January 19, 2011ALBUQUERQUE, N.M. – OSO BioPharmaceuticals Manufacturing, LLC, has named Craig Mastenbaum director of new business development for its West Coast market.

Mastenbaum brings to OsoBio more than 30 years of leadership experience in clinical and contract liquid, lyophilized, ampule and syringe product manufacturing. Most recently, he was senior director for clinical and contract manufacturing for Dendreon Corp., a biotechnology company that develops anti-cancer agents.

“Craig has personally directed both the in-house and outsourced manufacturing of complex, sterile liquid pharmaceutical products and been responsible for ensuring key performance and quality assurance indicators,” said Milton Boyer, vice president of business development and sales. “He understands exactly what clients are looking for and how OsoBio can best meet their needs.”

Previously, Mastenbaum served as vice president of manufacturing and business development at Hollister-Stier Laboratories, where he quadrupled contract revenues, and as director of parenteral operations at Chiron Corp. He holds a bachelor’s of arts degree in microbiology from Rutgers University and a master’s degree in business administration from Gonzaga University.

OSO BioPharmaceuticals Manufacturing, LLC, is a contract manufacturing organization (CMO) focusing on biologic and pharmaceutical injectables.
Headquartered in Albuquerque, N.M., OsoBio specializes in products requiring complex handling, including highly potent compounds. Responsiveness, attention to detail and clear communication are the hallmarks of our client care.

OsoBio surpasses quality-assurance expectations within our industry. Our employees are industry veterans who provide innovative solutions to our clients’ most difficult projects. To learn more about our company and the value we offer clients, visit www.OsoBio.com.

Media contact: Milton Boyer, VP business development and sales, 706.694.2514